Armata Pharmaceuticals, Inc. (ARMP) Stock Profile — Insider Trades & Financials

Net Income-$124.3M

EPS$-1.37

Market Cap$444.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Deborah Birx

CEO & Executive Director

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The companyâs product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.

Employees: 60
Headquarters: Los Angeles, California, United States
Website

⚡

Core Efficiency

ROE?

56.86%

ROA?

-161.67%

D/E Ratio?

-1.35

📊

Profitability Ratios

Current Ratio?

1.19

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 5, 2026 (in 149 days)

Annual Report (10-K) — Based on filing pattern

Sep 5, 2026

Predicted10-K

Mar 25, 2026

10-KQ4 20257d after period end

Mar 25, 2026

10-KFY 202584d after period end

Nov 12, 2025

10-QQ3 20258d after period end

Aug 12, 2025

10-QQ2 20256d after period end

May 14, 2025

10-QQ1 20256d after period end

Mar 21, 2025

10-KQ4 202421d after period end

Mar 21, 2025

10-KFY 202580d after period end

Nov 13, 2024

10-QQ3 20245d after period end

Loading company sections...

Armata Pharmaceuticals, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness